Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Porton Pharma Solutions Gelecekteki Büyüme

Future kriter kontrolleri 4/6

Porton Pharma Solutions kazanç ve gelirin sırasıyla yıllık 109.8% ve 19.3% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 109.7% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 4.1% olacağı tahmin edilmektedir.

Anahtar bilgiler

109.8%

Kazanç büyüme oranı

109.7%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	18.5%
Gelir büyüme oranı	19.3%
Gelecekteki özkaynak getirisi	4.1%
Analist kapsamı	Low
Son güncelleme	20 Sep 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Porton Pharma Solutions Ltd.'s (SZSE:300363) 39% Price Boost Is Out Of Tune With Revenues

Sep 30

Porton Pharma Solutions (SZSE:300363) Has Debt But No Earnings; Should You Worry?

Sep 25

Is Porton Pharma Solutions (SZSE:300363) Weighed On By Its Debt Load?

Jun 26

Analysts Just Shaved Their Porton Pharma Solutions Ltd. (SZSE:300363) Forecasts Dramatically

May 02

Does Porton Pharma Solutions (SZSE:300363) Have A Healthy Balance Sheet?

Mar 26

Porton Pharma Solutions Ltd.'s (SZSE:300363) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Mar 04

Kazanç ve Gelir Büyüme Tahminleri

SZSE:300363 - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (CNY Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	4,184	300	N/A	818	2
12/31/2025	3,923	186	N/A	542	4
12/31/2024	3,032	-188	N/A	647	3
6/30/2024	2,681	-314	-879	-15	N/A
3/31/2024	2,966	-122	-614	355	N/A
12/31/2023	3,667	267	-501	629	N/A
9/30/2023	4,854	880	-15	1,199	N/A
6/30/2023	5,460	1,203	1,709	2,876	N/A
3/31/2023	6,970	1,928	1,359	2,593	N/A
1/1/2023	7,035	2,005	1,391	2,564	N/A
9/30/2022	6,293	1,741	1,325	2,533	N/A
6/30/2022	5,763	1,522	-299	850	N/A
3/31/2022	4,005	818	-103	779	N/A
1/1/2022	3,105	524	-297	480	N/A
9/30/2021	2,614	446	-146	415	N/A
6/30/2021	2,402	408	14	487	N/A
3/31/2021	2,224	364	-46	439	N/A
12/31/2020	2,072	324	110	504	N/A
9/30/2020	1,958	289	177	524	N/A
6/30/2020	1,852	251	189	400	N/A
3/31/2020	1,689	217	240	441	N/A
12/31/2019	1,551	186	176	351	N/A
9/30/2019	1,430	163	148	290	N/A
6/30/2019	1,299	159	182	337	N/A
3/31/2019	1,225	119	40	174	N/A
12/31/2018	1,185	124	25	194	N/A
9/30/2018	1,191	134	6	163	N/A
6/30/2018	1,101	79	-182	-20	N/A
3/31/2018	1,039	73	N/A	170	N/A
12/31/2017	1,184	107	N/A	291	N/A
9/30/2017	1,242	121	N/A	276	N/A
6/30/2017	1,307	138	N/A	458	N/A
3/31/2017	1,399	182	N/A	398	N/A
12/31/2016	1,327	171	N/A	285	N/A
9/30/2016	1,194	148	N/A	183	N/A
6/30/2016	1,097	148	N/A	74	N/A
3/31/2016	1,029	125	N/A	-14	N/A
12/31/2015	1,021	110	N/A	112	N/A
9/30/2015	1,155	142	N/A	349	N/A
6/30/2015	1,156	138	N/A	316	N/A
3/31/2015	1,072	127	N/A	304	N/A
12/31/2014	987	125	N/A	122	N/A
9/30/2014	719	71	N/A	-90	N/A
6/30/2014	739	88	N/A	-9	N/A
3/31/2014	723	90	N/A	42	N/A
12/31/2013	734	100	N/A	114	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: 300363 önümüzdeki 3 yıl içerisinde kârlı hale gelmesi öngörülüyor; bu da tasarruf oranından ( 2.9% ) daha hızlı bir büyüme olarak değerlendiriliyor.

Kazançlar ve Piyasa: 300363 önümüzdeki 3 yıl içerisinde karlı hale gelmesi öngörülüyor ki bu da ortalama piyasa büyümesinin üzerinde kabul ediliyor.

Yüksek Büyüme Kazançları: 300363 önümüzdeki 3 yıl içinde karlı hale gelmesi bekleniyor.

Gelir ve Pazar: 300363 şirketinin gelirinin (yıllık 19.3% ) CN pazarından (yıllık 13.2% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: 300363 şirketinin gelirinin (yıllık 19.3% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: 300363 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 4.1 %).

Porton Pharma Solutions Gelecekteki Büyüme

Future kriter kontrolleri 4/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Price target decreased by 29% to CN¥20.30

Price target decreased by 11% to CN¥33.00

Consensus EPS estimates increase by 12%

Consensus EPS estimates increase by 12%

Consensus EPS estimates fall by 10%

Price target decreased by 9.8% to CN¥37.00

Recent updates

Porton Pharma Solutions Ltd.'s (SZSE:300363) 39% Price Boost Is Out Of Tune With Revenues

New minor risk - Share price stability

Porton Pharma Solutions Ltd. to Report Q3, 2024 Results on Oct 25, 2024

Porton Pharma Solutions (SZSE:300363) Has Debt But No Earnings; Should You Worry?

Second quarter 2024 earnings released: CN¥0.14 loss per share (vs CN¥0.20 profit in 2Q 2023)

Porton Pharma Solutions Ltd. to Report First Half, 2024 Results on Aug 28, 2024

Price target decreased by 29% to CN¥20.30

Is Porton Pharma Solutions (SZSE:300363) Weighed On By Its Debt Load?

Porton Pharma Solutions Ltd. Announces Final Cash Dividend on A Shares for the Year 2023, Payable on 29 May 2024

Analysts Just Shaved Their Porton Pharma Solutions Ltd. (SZSE:300363) Forecasts Dramatically

Porton Pharma Solutions Ltd., Annual General Meeting, May 20, 2024

First quarter 2024 earnings released: CN¥0.17 loss per share (vs CN¥0.56 profit in 1Q 2023)

Porton Pharma Solutions Ltd., Annual General Meeting, May 20, 2024

Porton Pharma Solutions Ltd. to Report Q1, 2024 Results on Apr 27, 2024

Does Porton Pharma Solutions (SZSE:300363) Have A Healthy Balance Sheet?

Porton Pharma Solutions Ltd.'s (SZSE:300363) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Investor sentiment deteriorates as stock falls 15%

Porton Pharma Solutions Ltd. to Report Fiscal Year 2023 Results on Mar 30, 2024

Price target decreased by 11% to CN¥33.00

Consensus EPS estimates increase by 12%

Consensus EPS estimates increase by 12%

Consensus EPS estimates fall by 10%

New major risk - Earnings quality

Third quarter 2023 earnings released: EPS: CN¥0.075 (vs CN¥0.67 in 3Q 2022)

New major risk - Revenue and earnings growth

Investor sentiment improves as stock rises 19%

Price target decreased by 9.8% to CN¥37.00

Consensus EPS estimates fall by 43%, revenue upgraded

Second quarter 2023 earnings released: EPS: CN¥0.20 (vs CN¥1.53 in 2Q 2022)

Porton Pharma Solutions Ltd. to Report First Half, 2023 Results on Aug 19, 2023

Upcoming dividend of CN¥1.11 per share at 3.2% yield

Consensus EPS estimates fall by 26%

Full year 2022 earnings: EPS exceeds analyst expectations

Price target decreased by 8.7% to CN¥70.63

Investor sentiment improved over the past week

High number of new directors

Consensus revenue estimates fall by 11%

Third quarter 2022 earnings released: EPS: CN¥0.67 (vs CN¥0.27 in 3Q 2021)

Investor sentiment improved over the past week

Consensus EPS estimates increase by 21%

Price target decreased to CN¥104

Second quarter 2022 earnings released: EPS: CN¥1.53 (vs CN¥0.23 in 2Q 2021)

Porton Pharma Solutions Ltd. (SZSE:300363) announces an Equity Buyback for CNY 100 million worth of its shares.

Investor sentiment improved over the past week

High number of new directors

High number of new and inexperienced directors

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Porton Pharma Solutions Ltd. Announces Final Dividend for 2021, Payable on 28 April 2022

Porton Pharma Solutions Ltd. Approves Cash Dividend for 2021

Consensus revenue estimates increase by 52%

Porton Pharma Solutions Ltd., Annual General Meeting, Apr 18, 2022

Porton Pharma Solutions Ltd., Annual General Meeting, Apr 18, 2022

Porton Pharma Solutions Ltd. Proposes Final Cash Dividend for 2021

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings released: EPS CN¥0.27 (vs CN¥0.20 in 3Q 2020)

Porton Pharma Solutions Ltd. (SZSE:300363) agreed to acquire 70% stake in Hubei Yuyang Pharmaceutical Co., Ltd. from a group of shareholders for approximately CNY 170 million.

Second quarter 2021 earnings released: EPS CN¥0.23 (vs CN¥0.16 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.16 (vs CN¥0.09 in 1Q 2020)

Porton Pharma Solutions Ltd. Announces on 15 March 2021 the Profit Distribution Proposal for 2020

Porton Pharma Solutions Ltd., Annual General Meeting, Apr 06, 2021

Full year 2020 earnings released: EPS CN¥0.61 (vs CN¥0.35 in FY 2019)

Investor sentiment deteriorated over the past week

Full year 2020 earnings released: EPS CN¥0.60 (vs CN¥0.35 in FY 2019)

Revenue beats expectations

New 90-day high: CN¥46.67

Zhangjiagang Zhuoyuan Investment Partnership (Limited Partnership) completed the acquisition of 5.24% stake in Porton Pharma Solutions Ltd. (SZSE:300363) from Ju Nianfeng, Tao Rong, and Zhang Hebing.

Porton Pharma Solutions Ltd. to Report Fiscal Year 2020 Results on Mar 13, 2021

New 90-day high: CN¥42.13